Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVISE-AF: Rivaroxaban 15 mg vs 20 mg in Non-valvular Atrial Fibrillation
KCT0008340Phase 4Not yet recruiting
- Sponsor
- Samjin Pharmaceutical Co., Ltd.
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of rivaroxaban in Atrial fibrillation (AFib), sponsored by Samjin Pharmaceutical Co., Ltd.. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
rivaroxaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on KCT0008340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008340.